<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14157">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922582</url>
  </required_header>
  <id_info>
    <org_study_id>404-C-201</org_study_id>
    <nct_id>NCT02922582</nct_id>
  </id_info>
  <brief_title>Study of Local Administration of DepoTXA for Reduced Bleeding in Subjects Undergoing TKA</brief_title>
  <official_title>A Randomized, Single-Blind, Active-Controlled, Dose-Ranging Study To Evaluate PK, Safety, and Efficacy of Local Administration of DepoTXA for Reduced Post-Surgical Bleeding in Subjects Undergoing TKA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, single-blind, active-controlled dose-ranging study in
      subjects scheduled to undergo total knee arthroplasty (TKA). Approximately 60 subjects (15
      per arm) are planned for enrollment. Subjects will be randomized in a 1:1:1:1 ratio to
      receive either DepoTXA 400 mg, DepoTXA 800 mg, DepoTXA 1200 mg, or IV TXA (Cyklokapron® 1
      gram).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-versus-time curve (AUC) from time 0 to the last collection time after drug administration (AUC0-tlast)</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-versus-time curve from time 0 extrapolated to infinity after drug administration (AUC0-∞)</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The apparent terminal elimination rate constant (λz)</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The apparent terminal elimination half-life (t1/2el)</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Post-Surgical Hgb Levels</measure>
    <time_frame>120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Post-Surgical Hct Levels</measure>
    <time_frame>120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Transfusions</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 90 degree passive and active knee flexion at 24, 48, and 72 hours using a goniometer</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Knee flexion (passive and active) will be measured by a standard physical medicine/rehabilitation technique with the patient stable in either a sitting or supine position using a goniometer, aligning the fulcrum of the goniometer with the fulcrum of the joint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical therapy assessment (TUG test)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of treatment-emergent adverse events and serious adverse events</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>TXA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 gram IV intraoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DepoTXA 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg Intracapsular</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DepoTXA 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg Intracapsular</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DepoTXA 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200mg Intracapsular</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DepoTXA</intervention_name>
    <arm_group_label>DepoTXA 400mg</arm_group_label>
    <arm_group_label>DepoTXA 800mg</arm_group_label>
    <arm_group_label>DepoTXA 1200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>TXA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled to undergo elective unilateral open TKA under general, spinal, or regional
             anesthesia.

          2. American Society of Anesthesiology (ASA) physical status 1, 2, or 3.

          3. Female subject must be surgically sterile; or at least 2 years postmenopausal; or
             have a monogamous partner who is surgically sterile; or practicing double-barrier
             contraception; or practicing abstinence (must agree to use double-barrier
             contraception in the event of sexual activity); or using an insertable, injectable,
             or transdermal, contraceptive approved by the FDA for greater than 2 months prior to
             screening and commit to the use of an acceptable form of birth control for the
             duration of the study and for 30 days after completion of the study.

          4. Able to provide informed consent, adhere to the study visit schedule, and complete
             all study assessments.

        Exclusion Criteria:

          1. Currently pregnant, nursing, or planning to become pregnant during the study or
             within 1 month after study drug administration.

          2. Planned concurrent surgical procedure (e.g., bilateral TKA).

          3. Prior open knee surgery on ipsilateral knee. Prior arthroscopy is permitted.

          4. Subjects taking a medication with a known procoagulant effect (e.g., combination
             hormonal contraceptives, Factor IX complex concentrates or anti-inhibitor coagulant
             concentrates, or all-trans retinoic acid).

          5. Contraindication or hypersensitivity to TXA.

          6. History of thrombosis or prior VTE.

          7. Known coagulopathy or active intravascular clotting.

          8. Prior myocardial infarction.

          9. Prior cardiovascular accident (stroke) or subarachnoid hemorrhage.

         10. History of epilepsy.

         11. Presence of an intravascular stent.

         12. History of impaired kidney function, chronic respiratory disease, rheumatoid
             arthritis, coagulopathy, or loss of sensation in extremities.

         13. Renal insufficiency (serum creatinine level &gt;2 mg/dL).

         14. Anemia (Hgb level &lt;10 g/dL).

         15. Uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with
             study assessments.

         16. Acquired defective color vision.

         17. Malignancy in the last 2 years, with the exception of non-metastatic basal cell or
             squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.

         18. Suspected or known history of drug or alcohol abuse within the previous year.

         19. Body weight &lt;50 kg (110 pounds) or a body mass index &gt;44 kg/m2.

         20. Administration of an investigational drug within 30 days or 5 elimination half-lives
             of such investigational drug, whichever is longer, prior to study drug
             administration, or planned administration of another investigational product or
             procedure during the subject's participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James B Jones, MD, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Cirillo</last_name>
    <email>chris.cirillo@pacira.com</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 3, 2016</lastchanged_date>
  <firstreceived_date>September 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
